It is an established concept in modern cancer research that structural and functional alterations of cellular genes are instrumental in the transformation of a normal cell into a malignant phenotype. Although to date no causal relationship has been proved to link steroid-hormone effects to the induction of chromosomal alterations in an animal system, steroid hormones have been shown to be capable of producing chromosomal abnormalities in cultured cells (1,2). In addition, Banduhn and Obe (3) 
It is an established concept in modern cancer research that structural and functional alterations of cellular genes are instrumental in the transformation of a normal cell into a malignant phenotype. Although to date no causal relationship has been proved to link steroid-hormone effects to the induction of chromosomal alterations in an animal system, steroid hormones have been shown to be capable of producing chromosomal abnormalities in cultured cells (1, 2) . In addition, Banduhn and Obe (3) showed that both diethylstilbestrol (DES) and estradiol are capable of inducing genomic mutations in cultured cells, and Wheeler et al. (4) showed that estradiol and DES are potent inhibitors of mitosis in in vitro cell cultures. A similar study by Tsutsui et al. (5) suggested that estrogen can induce two types of genetic changes, one involving numerical chromosome change (aneuploidy) with no evident DNA damage and another associated with structural chromosomal aberrations induced by estrogen catechol metabolites. Hillbertz-Nilsson and Forsberg (6) reported estrogen-induced aneuploidy in the epithelial cells from the uterine cervix of a neonatal mouse. Their report, along with those of Endo et al. (7) and Hajek et al. (8, 9) , suggests the possibility that perinatal exposure to estrogen results in chromosomal aberrations in the same target tissues in which neoplasia occurs after the in vivo administration of estrogen.
Evolution of Malignancy
Experimental studies of carcinogenesis and clinical evidence suggest that the development of a malignant tumor is a gradual evolutionary process during which tumor cells progressively acquire permanent qualitatively different characteristics (10) . Genetic instability of tumor cells has been found to be greatly enhanced over that of normal cells, and amplification of DNA may be one of the mechanisms that leads to the emergence of clonal populations that have increasingly malignant properties (11, 12 (14) reported a positive correlation between histological and cytogenetic analysis with more aggressive and atypical tumors. They showed that 10 to 20 weeks of exposure to a promoter stimulated the progression of a papilloma (benign diploid lesion) to a hyperdiploid (neoplastic) lesion. Their results suggest that aneuploidy may play a mechanistic role in the sequence of events that lead to neoplasia in epithelial tissue. It has also been suggested that the chemical induction of skin tumors in mice can be subdivided into at least three stages: initiation, promotion, and tumor development (14) . The progression from initiation to carcinoma is thought to involve the clonal expansion of initiated epidermal cells, which results in the formation of benign tumors. The conversion of benign tumors to carcinomas is thought to require an additional cellular (i.e., genomic) change. The hormonal induction of tumors may involve a similar process. Unlike chemical induction in the mouse skin tumorigenesis model, perinatal exposure to estrogen during a critical period during the development of the neonatal mouse resulted in a state of continuous proliferation of cervicovaginal epithelium, even in the absence of estrogen. However, similar to the chemical induction of skin tumors, perinatal exposure to estrogen may result in the selection of a clonal population. It is the development of cervicovaginal tumors in intact mice that indicates that a particular clonal population may be under the influence of estrogen (Figure 1 ).
The development of this particular clonal population and the subsequent development of tumors is time dependent (15) (Table 1 ). In addition, perinatal exposure to estrogen before 3 days after birth, followed by continuous secondary estrogen administration beginning at 10 days of age, reduces the latency period required for the nuclear DNA content of the cervicovaginal epithelium to increase (9) . These data indicate that, like the human fetus, a critical period exists in mice for the induction of cervicovaginal abnormalities. The critical period for the induction of nuclear DNA changes appears to be similar to the critical period for the induction of cervicovaginal tumors. In addition to the numerical chromosomal changes, a change in the expression of certain proteins occurs ( Figure 1 ). In our neonatal mouse model after exposure to estrogen, the expression of HER2/neu ( Figure 2 ) and c-fos was altered (16) (18) . At the end of the 1960s, evidence began to emerge from clinical studies that treating pregnant women with DES for threatened abortion in the first trimester correlated with the appearance of vaginal adenocarcinoma in their young daughters. During the decade following the description of the initial six cases of vaginal adenocarcinoma in young women after exposure to DES or chemically related hormones in utero, a wealth of information became available concerning the pathology and pathogenesis of disorders related to prenatal exposure to these agents (19) . Presently, it is estimated that in utero DES exposure of the female human fetus has resulted in approximately 519 documented cases of vaginal and cervical clear-cell adenocarcinoma (20) . This represents only a small percentage of the as yet unknown total number of young women exposed to DES in utero. The population at risk has been estimated to be as great as 2 million females (21, 22) .
As reported by R. Newbold, studies of DES using the neonatal mouse have been and continue to be productive for a variety of reasons. She and her associates used the mouse model to study the effects of DES and demonstrated that the majority of DES-related developmental abnormalities observed in humans could be reproduced in mice. Conversely, she provided data useful as clinical guides for as yet unseen or unrecognized human conditions. These effects may also illustrate potential adverse health effects from lower potency estrogens.
It is important to consider the role of estrogens in the environment, especially their effects on development. For instance, many organochlorine pollutants such as PCBs present in the environment have the ability to weakly bind to the estrogen receptor (23) . However, at present, it is unknown whether they also have the ability to induce tumorigenesis as observed for potent estrogens. Both environmental and genetic interactions play equally important roles in human disease.
Developmental Abnormalities
Resulting from Exposure to Estrogenic Chemicals Ando et al. (24) demonstrated that estrogenic chemical compounds can cross the placenta to the fetus and can be transferred via breast milk to newborns. In the female fetus, previous studies have indicated that the organs most susceptible to developmental effects from endocrine-disrupting chemicals include the mammary gland, fallopian tubes, uterus, cervix, and vagina (18) . Recent findings demonstrated that 177a-estradiol, a weak estrogen, can cause reproductive abnormalities similar to those reported in BALB/c mice exposed perinatally to natural and synthetic estrogens. These findings raise the possibility of longterm consequences resulting from early exposure to weak environmental estrogens (25) In what other tissues could environmental exposure to estrogenic compounds potentially result in developmental abnormalities? S. Migliaccio and colleagues studied the effect of DES exposure on the developmental programming of bone cell metabolism. Osteoporosis is a condition that over decades robs the skeleton of resources until the bone is weak enough to sustain a spontaneous fracture. In the study of ER in bone tissue, estrogen was found to modulate the activity of bone cells in vitro.
To address the question of whether changes in estrogen levels during development could affect skeletal characteristics, Migliaccio and co-workers used the neonatal mouse model to evaluate the potential effects of environmental estrogens on developing bone tissue (33). What they observed was the effects of DES on the length of the femur. In addition, perinatal exposure to DES affected the density of the bone tissue. Basically, the length of the femur decreased and the bone mass increased. She also observed that bone is more sensitive to the disruptive effects of DES at lower levels of exposure. Although no definitive study has been done with women exposed to DES in utero, there have been a few self-reported cases of spondylolisthesis.
Summary
The sum of the evidence supports the necessity to continue to investigate the developmental effects of estrogenic and antiestrogenic compounds when exposure occurs early in life. Additional studies will answer questions relevant to the molecular definition of the developmental or carcinogenic effects of estrogens such as hormoneinduced gene alterations. These studies also support the need to use the neonatal mouse model to demonstrate the consequences of reproductive and nonreproductive stem-cell exposure to estrogenic compounds.
